全文获取类型
收费全文 | 209907篇 |
免费 | 15561篇 |
国内免费 | 744篇 |
专业分类
耳鼻咽喉 | 2284篇 |
儿科学 | 5482篇 |
妇产科学 | 4304篇 |
基础医学 | 27098篇 |
口腔科学 | 4510篇 |
临床医学 | 19997篇 |
内科学 | 44882篇 |
皮肤病学 | 2754篇 |
神经病学 | 20301篇 |
特种医学 | 6951篇 |
外国民族医学 | 13篇 |
外科学 | 32913篇 |
综合类 | 3411篇 |
现状与发展 | 2篇 |
一般理论 | 291篇 |
预防医学 | 19062篇 |
眼科学 | 4372篇 |
药学 | 14387篇 |
1篇 | |
中国医学 | 374篇 |
肿瘤学 | 12823篇 |
出版年
2023年 | 841篇 |
2022年 | 1403篇 |
2021年 | 3439篇 |
2020年 | 2105篇 |
2019年 | 3390篇 |
2018年 | 3967篇 |
2017年 | 3212篇 |
2016年 | 3410篇 |
2015年 | 4066篇 |
2014年 | 6095篇 |
2013年 | 8822篇 |
2012年 | 13123篇 |
2011年 | 14319篇 |
2010年 | 8096篇 |
2009年 | 7304篇 |
2008年 | 13588篇 |
2007年 | 14424篇 |
2006年 | 13918篇 |
2005年 | 14392篇 |
2004年 | 13806篇 |
2003年 | 12899篇 |
2002年 | 12435篇 |
2001年 | 1873篇 |
2000年 | 1458篇 |
1999年 | 2045篇 |
1998年 | 2828篇 |
1997年 | 2437篇 |
1996年 | 2205篇 |
1995年 | 1953篇 |
1994年 | 1755篇 |
1993年 | 1655篇 |
1992年 | 1208篇 |
1991年 | 1149篇 |
1990年 | 1053篇 |
1989年 | 952篇 |
1988年 | 1011篇 |
1987年 | 1018篇 |
1986年 | 998篇 |
1985年 | 1081篇 |
1984年 | 1478篇 |
1983年 | 1461篇 |
1982年 | 1814篇 |
1981年 | 1639篇 |
1980年 | 1555篇 |
1979年 | 812篇 |
1978年 | 958篇 |
1977年 | 932篇 |
1976年 | 831篇 |
1975年 | 682篇 |
1974年 | 666篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献12.
Katja T. Turunen Vasiliki Pletsa Panagiotis Georgiadis John K. Triantafillidis Dimitrios Karamanolis 《Nutrition and cancer》2016,68(4):560-567
The aim of the study was to determine the effect of β-glucan on the cytotoxicity and genotoxicity of polypectomized patient's fecal water (FW). Polypectomized volunteers (n = 69) were randomly assigned to consume bread with or without β-glucan, for 3 months. FW was collected at the beginning (t = 0), the 30th and 90th day and 2 wk after the intervention. Cytotoxicity and genotoxicity were estimated on Caco-2 cells, using trypan blue exclusion test and comet assay, respectively. Gastrointestinal symptoms were recorded and subjects kept a 3-day food diary at baseline and after completion. Trypan blue exclusion test revealed cell survival of approximately 87% after incubation with FW. The FW samples showed 49% genotoxicity at the baseline. Genotoxicity in the intervention group decreased during the trial reaching statistical significance on the 90th day compared to control. An increase was noticed 2 wk after the trial, but it still remained significantly lower compared to control. Group-specific analysis for β-glucan also revealed significant decrease in the genotoxicity on the 90th day compared to baseline. β-glucan ingestion in polypectomized patients significantly decreased the genotoxicity of their FW. Our findings suggest that β-glucan consumption could possibly provide protection against colon cancer development. 相似文献
13.
Rebecca L. King Albert C. Yan Debora R. Sekiguchi John K. Choi 《Journal of cutaneous pathology》2015,42(12):1012-1017
Reactive lymphoid infiltrates of the skin composed predominantly of gamma‐delta (γδ) T cells are not well described in the literature. Herein we report a case of an otherwise healthy 4‐year‐old male who presented with a waxing and waning papular rash characterized by small, discrete crusted papules spread across his trunk, face and extremities. Clinical evaluation revealed no evidence of systemic disease. Microscopic examination revealed a dermal, perivascular infiltrate of highly atypical lymphocytes with a γδ T cell phenotype, worrisome for primary cutaneous γδ T cell lymphoma. The clinical course, however, was that of a reactive condition and prompted consideration of a diagnosis of pityriasis lichenoides et varioliformis acuta (PLEVA) and lymphomatoid papulosis (LyP). In many ways, this case defies current classification schemes and seems to expand the spectrum of reactive γδ T cell infiltrates of the skin. 相似文献
14.
15.
16.
17.
18.
19.
Dan Azagury Tara E Mokhtari Luis Garcia Ulysses S Rosas Trit Garg Homero Rivas John Morton 《Surgery》2019,165(3):565-570
Background
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, and laparoscopic adjustable gastric banding all lead to substantial weight loss in obese patients. Long-term weight loss can be highly variable beyond 1-year postsurgery. This study examines and compares the frequency distribution of weight loss and lack of treatment effect rates after laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, and laparoscopic adjustable gastric banding.Methods
A total of 1,331 consecutive patients at a single academic institution were reviewed from a prospectively collected database. Preoperative data collected included demographics, body mass index, and percent excess weight loss. Postoperative BMI and %EWL were collected at 12, 24, and 36 months. Percent excess weight loss was analyzed by the percentiles of excess weight lost, and the distribution of percent excess weight loss was evaluated in 10% increments. Lack of a successful treatment effect was defined as <25% excess weight loss.Results
Of the 1,331 patients, 72.4% (963) underwent laparoscopic Roux-en-Y gastric bypass, 18.3% (243) laparoscopic sleeve gastrectomy, and 9.4%(125) laparoscopic adjustable gastric banding. Mean percent excess weight loss was greatest for laparoscopic Roux-en-Y gastric bypass, followed by laparoscopic sleeve gastrectomy, and then by laparoscopic adjustable gastric banding at every time point: at 2 years mean percent excess weight loss was 77.9± 24.4 for laparoscopic Roux-en-Y gastric bypass, 50.8 ± 25.8 for laparoscopic sleeve gastrectomy, and 40.8± 25.9 for laparoscopic adjustable gastric banding (P < .0001). The rates of a successful treatment effect s for laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, and laparoscopic adjustable gastric banding were 0.9%, 5.2%, and 24.3% at 1 year; 0.3%, 11.1%, and 26.0% at 2 years; and 1.0%, 25.3%, and 30.2% at 3 years. At 1 year, the odds ratio of lack of a successful treatment effect of laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass was 6.305 (2.125–19.08; P?=?.0004), the odds ratio for laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass was 36.552 (15.64–95.71; P < .0001), and the odds ratio for laparoscopic adjustable gastric banding versus laparoscopic sleeve gastrectomy was 5.791 (2.519–14.599; P < .0001). At 2 years, the odds ratio for laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass increased to 70.7 (9.4–531.7; P < .0001), the odds ratio for laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass increased to 128.1 (16.8–974.3; P < .0001), and the odds ratio for laparoscopic adjustable gastric banding versus laparoscopic sleeve gastrectomy decreased to 1.8 (0.9–3.6; P?=?.09).Conclusion
This study emphasizes the existing variability in weight loss across bariatric procedures as well as in the lack of a treatment effect for each procedure. Although laparoscopic adjustable gastric banding has the greatest rate of a lack of a successful treatment effect, the rate remained stable over 3 years postoperatively. Laparoscopic sleeve gastrectomy showed a doubling in the rate of a lack of a successful treatment effect every year reaching 25% at year 3. The rates for lack of a successful treatment effect for laparoscopic Roux-en-Y gastric bypass remained stable at about 1% for the first 3 years postoperatively. 相似文献20.